Xarelto (Rivaroxaban): The Blood Thinner with No Off Switch

When Stopping the Bleed Was Impossible

Xarelto (rivaroxaban), jointly marketed by Bayer and Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), was approved by the FDA in 2011 as a next-generation anticoagulant — a blood thinner designed to prevent dangerous clots in patients with atrial fibrillation, deep vein thrombosis, and other conditions. It was marketed as a convenient alternative to warfarin, requiring no routine blood monitoring and offering a once-daily dosing schedule.

What was not prominently disclosed, however, was a critical and potentially fatal limitation: unlike warfarin, there was initially no approved reversal agent for Xarelto.

The Fatal Bleeding Risk

Anticoagulants inherently carry bleeding risks, but the inability to quickly reverse Xarelto's effects in emergency situations — such as a traumatic injury or urgent surgery — meant that patients experiencing uncontrolled bleeding had very few options. Thousands of patients suffered severe and fatal hemorrhagic events, including gastrointestinal bleeds and fatal intracranial hemorrhages. Physicians and emergency rooms were often left without effective tools to stop the bleeding.

Plaintiffs alleged that Bayer and Janssen downplayed this risk in marketing materials and failed to adequately warn patients and physicians about the lack of a reversal agent — information that could have been critical in treatment decisions.

The Litigation

More than 25,000 lawsuits were filed against Bayer and Janssen, consolidated into federal MDL proceedings. In 2019, Bayer and Janssen agreed to a $775 million settlement to resolve approximately 25,000 pending claims — one of the largest pharmaceutical settlements for a single drug at the time.

Regulatory and Safety Developments

The FDA ultimately approved Andexxa (andexanet alfa) in 2018 as a reversal agent for factor Xa inhibitors including Xarelto — years after millions of patients had already been prescribed the drug without this safety net. The Xarelto litigation underscored the importance of having reversal agents available before or concurrent with the approval of anticoagulants, and raised serious questions about the adequacy of informed consent when critical safety information is omitted from patient-facing materials.